Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma

Figure 1 Proliferation of HCC (A) and ECs (B) selectively inhibited by rVBMDMP (mean ± SD, n = 9). ^aP < 0.05 vs other cells.

Figure 2 Robust efficacy of rVBMDMP against HepG2 xenografts in nude mice (mean ± SD, n = 6). ^aP < 0.05, ^bP < 0.01 vs NS.

Figure 3 Accumulation of rVBMDMP in HepG2 xenografts in nude mice after treatment. A: NS; B: 20 mg/kg of 5-FU; C: 10 mg/kg of rVBMDMP; D: Quantification of rVBMDMP-positive areas in HepG2 xenografts. The data are expressed as mean ± SD (n = 6). ^aP < 0.05 vs NS.

Figure 4 Expression of PCNA in HepG2 xenografts in nude mice after treatment. A: NS; B: 20 mg/kg of 5-FU; C: 10 mg/kg of rVBMDMP; D: Quantification of PCNA-positive areas in HepG2 tumors. The data are expressed as mean ± SD (n = 6). ^aP < 0.05 vs NS.

Figure 5 Microvessel density of HepG2 xenografts in nude mice after treatment. A: NS; B: 20 mg/kg of 5-FU; C: 10 mg/kg of rVBMDMP; D: Quantification of microvessel density (CD31 staining) positive areas in HepG2 xenografts in nude mice. The data are expressed as mean ± SD (n = 6). ^aP < 0.05 vs NS.